 |
 |
Writer couldn't find the "." key on his computer ? > Date: Sat, 6 Jun 2015 12:07:40 +0200 > From: [log in to unmask] > Subject: Re: dyskinesia treatment trial > To: [log in to unmask] > > I love this sentence; > > 'The multi-center, 60-subject Phase 2b study in individuals with > Parkinson's disease is a double-blind, placebo-controlled, four-way > crossover, dose range finding, clinical trial designed to evaluate dose > response effect of repeated eltoprazine dosing on safety, tolerability and > dyskinesia severity using state-of-the-art rating scales, diaries and > motion sensors (ClinicalTrials.gov Identifier: NCT02439125).' > > > ;-)) > > Nic 63/21 > > > On 6 June 2015 at 05:29, Rayilyn Brown <[log in to unmask]> wrote: > > > http://money.cnn.com/news/newsfeeds/articles/globenewswire/10137013.htm > > Ray > > Rayilyn Brown > > Past Director AZNPF > > Arizona Chapter National Parkinson Foundation > > > > ---------------------------------------------------------------------- > > To sign-off Parkinsn send a message to: mailto: > > [log in to unmask] > > In the body of the message put: signoff parkinsn > > > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto:[log in to unmask] > In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn